Psyence Biomedical (PBM) Stock Price, News & Analysis

Company Overview

Psyence Biomedical, Inc. is a clinical-stage biotechnology company focused on developing innovative drug delivery solutions for neuropsychiatric and pain indications. Founded in 2020 and headquartered in Houston, Texas, the company’s proprietary technology platform centers on a biodegradable, microneedle patch designed for transdermal administration of therapeutic compounds. By harnessing this novel delivery approach, Psyence Biomedical aims to improve patient compliance, enhance bioavailability and offer controlled dosing of established and emerging investigational molecules.

The company’s lead product candidate leverages its microneedle system to administer a low-dose psychedelic compound for the potential treatment of depression, anxiety and other mood disorders. This patch technology is designed to allow for rapid onset, sustained release and minimal invasiveness compared with traditional oral or intravenous routes. In addition to its flagship program, Psyence Biomedical is exploring applications of its platform for acute and chronic pain relief using non-opioid analgesics. Preclinical studies have demonstrated promising pharmacokinetic profiles, and the company is advancing toward first-in-human trials in collaboration with academic research centers.

Psyence Biomedical serves markets in North America and Europe through strategic partnerships and research alliances aimed at accelerating clinical development and regulatory approval. The company benefits from a leadership team with deep experience in pharmaceutical development, medical device engineering and commercial operations. Chief Executive Officer Dr. Michelle Alvarez, who has over two decades of industry experience, is supported by Chief Scientific Officer Dr. Rahul Patel and a board of directors with expertise spanning biotechnology, venture capital and healthcare policy.

Key Stats

• Today's Range: $5.05 to $5.50
• 50-Day Range: $3.68 to $6.01
• 52-Week Range: $2.92 to $699.19
• Volume: 22,067 shs
• Average Volume: 114,010 shs
• Market Capitalization: $2.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Psyence Biomedical Stock Analysis - MarketRank™

Psyence Biomedical scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Psyence Biomedical.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Psyence Biomedical has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.92% of the float of Psyence Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Psyence Biomedical has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Psyence Biomedical has recently increased by 35.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Psyence Biomedical does not currently pay a dividend.

Dividend Growth

Psyence Biomedical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.92% of the float of Psyence Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Psyence Biomedical has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Psyence Biomedical has recently increased by 35.95%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Psyence Biomedical has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Psyence Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Psyence Biomedical is held by insiders.

Percentage Held by Institutions

77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PBM Stock Analysis - Frequently Asked Questions

How have PBM shares performed this year?

Psyence Biomedical's stock was trading at $16.8167 on January 1st, 2025. Since then, PBM stock has decreased by 69.9% and is now trading at $5.06.

How were Psyence Biomedical's earnings last quarter?

Psyence Biomedical Ltd. (NASDAQ:PBM) released its quarterly earnings results on Thursday, January, 23rd. The company reported $4.06 earnings per share for the quarter.

When did Psyence Biomedical's stock split?

Psyence Biomedical's stock reverse split on the morning of Monday, May 5th 2025.A 100-797 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Who are Psyence Biomedical's major shareholders?

Psyence Biomedical's top institutional shareholders include Parallel Advisors LLC (48.25%).

How do I buy shares of Psyence Biomedical?

Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Psyence Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), Saba Capital Income & Opportunities Fund (BRW), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ).

Company Calendar

• Last Earnings: 1/23/2025
• Today: 7/18/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBM
• Previous Symbol: NASDAQ:PBM
• CIK: 1985062
• Web: www.psyencebiomed.com
• Phone: 510-214-3750
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.04
• Quick Ratio: 11.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $1.78 per share
• Price / Cash Flow: 2.91
• Book Value: $11.83 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 570,000
• Free Float: 548,000
• Market Cap: $2.95 million
• Optionable: N/A
• Beta: 0.22